Adcock Ingram $1.2 Billion Buy By CFR Would Amass Huge Debt: Analyst
This article was originally published in PharmAsia News
If Chile's CFR Pharmaceuticals were to acquire South Africa's Adcock Ingram Holdings over the objections of its largest stakeholder, it would be taking on a huge debt load, analysts said.
You may also be interested in...
Biologic Exclusivity Provisions In USMCA Are Boon To Generics Industry; BIO Is 'Tremendously Worried'
Revised North American trade deal touted as enabling Congress to address crisis of high drug prices; requirement for 10 years biologic exclusivity is removed and language to allow incentives for generics added.
The Gilead subsidiary presented updated data at ASH for its first CD19-targeting CAR-T Yescarta and pivotal results for KTE-X19, which it plans to submit for US FDA approval in mantle cell lymphoma this year.
Hiring travails, inspection pre-announcement, lack of translators highlighted in congressional hearing on FDA foreign inspections.